Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma.
Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma.
复制标题
DOI：
10.3390/ijms24065493
复制
发表时间：
2023-03-13
影响因子：
5.6
通讯作者：
中科院分区：
文献类型：
--
作者：
淋巴瘤是一组异质性的疾病，往往需要他们的代谢程序，以满足细胞增殖的需求。淋巴瘤细胞中的代谢特征包括高葡萄糖摄取、糖酵解相关酶的表达失调、糖酵解和氧化代谢的双重能力、谷氨酰胺代谢升高和脂肪酸合成。这些异常的代谢变化导致肿瘤发生、疾病进展和对淋巴瘤化疗的抵抗。这种代谢重编程，包括葡萄糖、核酸、脂肪酸和氨基酸代谢，是一个动态过程，不仅由遗传和表观遗传变化引起，也由病毒感染影响的微环境变化引起。值得注意的是，一些关键的代谢酶和代谢产物可能在淋巴瘤的发生和发展中发挥重要作用。最近的研究发现，代谢途径可能对淋巴瘤亚型的诊断、表征和治疗具有临床影响。然而，确定与淋巴瘤代谢相关的生物标志物和治疗靶点的临床相关性仍然具有挑战性。本文就淋巴瘤代谢重编程的研究进展进行综述，主要包括糖、氨基酸、脂质代谢紊乱、代谢途径中分子的失调、肿瘤代谢以及潜在的代谢生物标志物。然后，我们直接或间接地讨论这些潜在的治疗靶点的策略。最后，对代谢重编程在淋巴瘤治疗中的应用前景进行了前景展望。
Lymphoma is a heterogeneous group of diseases that often require their metabolism program to fulfill the demand of cell proliferation. Features of metabolism in lymphoma cells include high glucose uptake, deregulated expression of enzymes related to glycolysis, dual capacity for glycolytic and oxidative metabolism, elevated glutamine metabolism, and fatty acid synthesis. These aberrant metabolic changes lead to tumorigenesis, disease progression, and resistance to lymphoma chemotherapy. This metabolic reprogramming, including glucose, nucleic acid, fatty acid, and amino acid metabolism, is a dynamic process caused not only by genetic and epigenetic changes, but also by changes in the microenvironment affected by viral infections. Notably, some critical metabolic enzymes and metabolites may play vital roles in lymphomagenesis and progression. Recent studies have uncovered that metabolic pathways might have clinical impacts on the diagnosis, characterization, and treatment of lymphoma subtypes. However, determining the clinical relevance of biomarkers and therapeutic targets related to lymphoma metabolism is still challenging. In this review, we systematically summarize current studies on metabolism reprogramming in lymphoma, and we mainly focus on disorders of glucose, amino acids, and lipid metabolisms, as well as dysregulation of molecules in metabolic pathways, oncometabolites, and potential metabolic biomarkers. We then discuss strategies directly or indirectly for those potential therapeutic targets. Finally, we prospect the future directions of lymphoma treatment on metabolic reprogramming.
登录
查看更多内容
影响因子：
11.2
作者：
Beloueche-Babari M;Wantuch S;Casals Galobart T;Koniordou M;Parkes HG;Arunan V;Chung YL;Eykyn TR;Smith PD;Leach MO
通讯作者：
Leach MO
影响因子：
11.2
作者：
Calvo-Vidal MN;Zamponi N;Krumsiek J;Stockslager MA;Revuelta MV;Phillip JM;Marullo R;Tikhonova E;Kotlov N;Patel J;Yang SN;Yang L;Taldone T;Thieblemont C;Leonard JP;Martin P;Inghirami G;Chiosis G;Manalis SR;Cerchietti L
通讯作者：
Cerchietti L
影响因子：
20.3
作者：
Campàs, C;López, JM;Gil, J
通讯作者：
Gil, J
影响因子：
3.2
作者：
Calvo-Vidal, M. Nieves;Cerchietti, Leandro
通讯作者：
Cerchietti, Leandro
影响因子：
3.5
作者：
Argyriou, Pinelopi;Papageorgiou, Sotirios G.;Rontogianni, Dimitra
通讯作者：
Rontogianni, Dimitra